Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report report published on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 1.9 %

Shares of NASDAQ EVOK opened at $4.14 on Friday. The stock has a market capitalization of $6.15 million, a PE ratio of -0.38 and a beta of 0.16. The stock’s fifty day simple moving average is $5.07 and its two-hundred day simple moving average is $5.37. Evoke Pharma has a 12-month low of $3.54 and a 12-month high of $15.84.

Institutional Trading of Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma at the end of the most recent reporting period.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.